Related Experiment Videos
Evaluation of potential chelating agents for radium
Gjermund Henriksen1, Per Hoff, Roy H Larsen
1Department of Chemistry, University of Oslo, Blindern, Norway.
Summary
The study evaluated radium chelators for targeted radionuclide therapy. Competition extraction experiments assessed the stability of radium-223 chelates, identifying promising agents for cancer treatment applications.
Area of Science:
- Radiochemistry
- Nuclear Medicine
- Oncology
Background:
- Targeted radionuclide therapy utilizes alpha-particle-emitting radionuclides like radium-223 for cancer treatment.
- Development of stable chelators is crucial for radiolabeling monoclonal antibodies with radium-223.
- Radium-223 has a half-life of 11.4 days, making it suitable for therapeutic applications.
Purpose of the Study:
- To evaluate the relative stability of radium-223 chelates with various linear and cyclic chelating agents.
- To identify potential chelators for developing radium-labeled monoclonal antibodies for targeted radionuclide therapy.
Main Methods:
- Competition extraction experiments were employed to assess the binding affinity and stability of radium-223 chelates.
- The study compared the performance of different linear and cyclic chelating agents in complexing radium.
Main Results:
- The relative stability of 223Ra-chelates with different chelating agents was determined.
- Certain linear and cyclic chelators demonstrated promising stability for radium binding.
Conclusions:
- The findings contribute to the selection of optimal chelators for radium-based targeted radionuclide therapy.
- Further development of these chelators could facilitate the clinical application of radium-223 in cancer treatment.